<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />


<meta name="author" content="Andrew Mertens" />

<meta name="date" content="2025-05-01" />

<title>Background and motivation</title>

<script src="site_libs/header-attrs-2.29/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">HOME</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="RWE_tutorial.html">Introduction: TL Roadmap in RWE</a>
</li>
<li>
  <a href="step0.html">Causal roadmap and case study introduction</a>
</li>
<li>
  <a href="step1v2.html">Roadmap step 1-alt</a>
</li>
<li>
  <a href="step1a.html">Roadmap step 1a</a>
</li>
<li>
  <a href="step1b.html">Roadmap step 1b</a>
</li>
<li>
  <a href="step2.html">Roadmap step 2</a>
</li>
<li>
  <a href="step3.html">Roadmap step 3</a>
</li>
<li>
  <a href="step4.html">Roadmap step 4</a>
</li>
<li>
  <a href="step5.html">Roadmap step 5</a>
</li>
<li>
  <a href="PS_analysis.html">Propensity score matching analysis</a>
</li>
<li>
  <a href="appendix.html">Appendix</a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">Background and motivation</h1>
<h4 class="author">Andrew Mertens</h4>
<h4 class="date">2025-05-01</h4>

</div>


<div id="background-prior-evidence" class="section level1">
<h1>0 Background &amp; Prior Evidence</h1>
<div id="why-aki-in-sof-vs-non-sof" class="section level2">
<h2>0.1 Why AKI in SOF vs non-SOF?</h2>
<p>Sofosbuvir (SOF) is renally eliminated as the inactive metabolite
GS-331007; transient rises in serum creatinine and rare case-reports of
biopsy-proven tubular injury have raised concern that the high
intratubular exposure during HCV therapy could precipitate acute kidney
injury (AKI). A pharmacovigilance “dry-run” flagged a disproportionality
signal for AKI in spontaneous reports linked to SOF-based regimens but
not to other direct-acting antivirals (DAAs) . Because many persons
treated for HCV already carry CKD risk factors (diabetes, cirrhosis, HIV
co-infection), parsing a true drug effect from background risk requires
carefully designed comparative real-world studies.</p>
</div>
<div id="regulatory-pharmacovigilance-context" class="section level2">
<h2>0.2 Regulatory &amp; pharmacovigilance context</h2>
<p>Since the 21st Century Cures Act, FDA and other regulators explicitly
encourage fit-for-purpose real-world evidence (RWE) to support
post-marketing safety evaluations. The Causal Roadmap and targeted
learning (TL) framework were developed to ensure that such RWE meets ICH
E9(R1) expectations for clearly defined estimands, transparent
identification assumptions and robust estimation . Parallel efforts
inside Sentinel have illustrated how Roadmap-driven analytics can be
operationalised for safety signals, including renal outcomes, in
claims-EHR linked data . The current AKI signal assessment therefore
sits at the intersection of (i) a plausible clinical toxicity, (ii) a
regulatory mandate for proactive pharmacovigilance, and (iii) emerging
analytic standards that emphasise explicit causal reasoning.</p>
</div>
<div id="prior-signal-detection-findings" class="section level2">
<h2>0.3 Prior signal-detection findings</h2>
<ul>
<li><p>Spontaneous reports &amp; literature. The index signal originated
from a published case report describing biopsy-confirmed AKI shortly
after SOF initiation and was reinforced by a small cluster of FAERS
submissions Report HCV and AKI supp….</p></li>
<li><p>Rapid supportive RWE analysis. Gilead’s comparative-safety study
in &gt;100 000 U.S. claims‐EHR patients (HealthVerity) used
propensity-score (PS) matching plus an as-treated Cox model. The
adjusted hazard ratio was 1.06 (95 % CI 0.96–1.16), suggesting no excess
risk, but residual confounding, mis-measured baseline eGFR and
informative censoring at regimen switch were acknowledged.</p></li>
<li><p>Causal Roadmap Tutorial. These draft materials reproduce those
analyses, document PS overlap and show how alternative estimands (e.g.,
treatment-policy vs while-on-treatment) or TL/TMLE estimators could
materially change inference</p></li>
</ul>
</div>
<div id="key-knowledge-gaps-roadmap" class="section level2">
<h2>0.4 Key knowledge gaps → roadmap</h2>
<table>
<colgroup>
<col width="10%" />
<col width="54%" />
<col width="36%" />
</colgroup>
<thead>
<tr class="header">
<th>Gap</th>
<th>Implication for inference</th>
<th>Roadmap response</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Potential time-varying confounding</strong> (e.g., eGFR
decline → regimen switch)</td>
<td>Censor-at-switch Cox may be biased</td>
<td>Specify alternative estimands (switch-censor vs model-crossover) and
apply TMLE with IPC weights</td>
</tr>
<tr class="even">
<td><strong>Outcome misclassification</strong> (ICD-10 AKI codes have ≤
60 % PPV)</td>
<td>Dilution bias toward the null</td>
<td>Run negative-control outcome checks</td>
</tr>
<tr class="odd">
<td><strong>Limited adjustment for high-dimensional confounders</strong>
in PS model</td>
<td>Residual confounding</td>
<td>Use Super Learner within TMLE; benchmark against high-dimensional PS
approaches</td>
</tr>
<tr class="even">
<td><strong>Regulatory relevance of different causal questions</strong>
(on-treatment safety vs population impact)</td>
<td>Choice of estimand drives decision-making</td>
<td>Map each stakeholder question to a precise estimand per ICH E9(R1);
implement Roadmap Steps 1-5 with diagnostics and sensitivity
analyses</td>
</tr>
</tbody>
</table>
<p>Addressing these gaps through the Causal Roadmap will yield estimands
that align with the clinical question (“Does SOF, when taken, increase
short-term AKI risk?”) and with regulatory decision needs, while
providing transparent diagnostics and sensitivity analyses to quantify
residual uncertainty.</p>
</div>
</div>
<div id="summary-of-existing-comparative-safety-analysis"
class="section level1">
<h1>0.5 Summary of existing comparative-safety analysis</h1>
<p><strong>Background and motivation.</strong> A pharmacovigilance
“dry-run” signal evaluation suggested a possible link between acute
kidney injury (AKI) and sofosbuvir-containing (SOF) direct-acting
antiviral (DAA) regimens used to treat chronic hepatitis C virus (HCV)
infection. To inform ongoing safety monitoring, Gilead undertook a
rapid, supportive real-world evidence (RWE) study comparing AKI risk in
patients initiating SOF-containing DAAs with those starting non-SOF
DAAs. The analysis leveraged a large US administrative-claims and
electronic‐medical-record data source (HealthVerity) covering more than
550 million patients (2015-2023) to provide timely, supplementary
evidence on whether the observed signal represented an increased,
clinically meaningful risk.</p>
<p><strong>Methods.</strong> A retrospective new-user cohort was drawn
from an HCV “standing cohort” of adults with ≥1 year of continuous
medical- and drug-coverage enrollment. Eligible initiators of SOF or
non-SOF DAAs between 1 October 2016 and 21 September 2023 entered
follow-up on the first dispense date (index). Exposure was handled “as
treated”: patients were censored 31 days after treatment discontinuation
or at crossover to the other DAA class. AKI was identified by ICD-10
codes (e.g., N17.x, N19, R34). Baseline demographics and 50+
comorbidities/medication variables were assessed in the prior year and
used to build a logistic-regression propensity score (PS). After 1:1
nearest-neighbor PS matching, AKI incidence was compared with Cox
proportional-hazards models: unadjusted, covariate-adjusted,
PS-stratified and PS-matched specifications served as sensitivity and
diagnostic checks.</p>
<p><strong>Results.</strong> Among 105 636 eligible patients (67 720
non-SOF; 37 916 SOF), crude AKI incidence was 8.9 vs 16.0 per 1000
persons, but crude comparability was poor. PS matching produced 37 220
well-balanced pairs (absolute covariate differences ≤1%). In the matched
analysis, AKI occurred in 608 SOF vs 605 non-SOF users over 26 387
person-years, yielding a hazard ratio (HR) of 1.14 (95% CI 1.00–1.30; p
= 0.05) and an absolute risk difference of +7.1 AKI cases per 1000
patients . Fully covariate-adjusted and PS-stratified Cox models in the
unmatched cohort gave similar, non-significant estimates (e.g., HR 1.11,
95% CI 0.99–1.26) . Model diagnostics indicated adequate overlap and
balance post-matching, but residual confounding could not be excluded.
Overall, the analysis did not confirm an elevated AKI risk for
SOF-containing DAAs; rather, after careful adjustment, risk estimates
were null to modest and statistically inconclusive, suggesting the
initial signal may reflect confounding or chance rather than a true
safety concern.</p>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
